ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
04 Jan 2023 12:14

Hong Kong Connect Flows Monthly: 12 Months of Inflows

We analyzed the Hong Kong Connect Scheme for December and highlight flows for Meituan, HKEX, China Unicom, Shenzhou Intl, Sensetime, Xiaomi, HSBC,...

Logo
388 Views
Share
03 Jan 2023 08:05

Hong Kong Connect Flows (Dec 30th): Tencent, Meituan

We analyzed the Hong Kong Connect Scheme for last week and highlight flows for Tencent Holdings Limited (700 HK) and Meituan (3690 HK).

Logo
421 Views
Share
30 Dec 2022 10:38

Hong Kong Buybacks Weekly (Dec 30th): Tencent, AIA, Productive Technologies

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
686 Views
Share
23 Dec 2022 16:10

Hong Kong Buybacks Weekly (Dec 23rd): Tencent, AIA, GWM

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
626 Views
Share
18 Dec 2022 10:00

HK Short Interest Weekly: Tencent, Ping An H&T, Xiaomi, Jiumaojiu, Wuxi Biologics, XPeng

We analyzed the latest HK SFC report for aggregate short position as of Dec 9th and highlight short interest changes in Tencent, Ping An H&T,...

Logo
613 Views
Share
x